about
Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnosticsMyocardial fibrosis: biomedical research from bench to bedside.Uncharted waters: rare and unclassified cardiomyopathies characterized on cardiac magnetic resonance imagingGetting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype.Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.MicroRNA signatures differentiate preserved from reduced ejection fraction heart failureScreening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide.Are beta2-agonists responsible for increased mortality in heart failure?Multidsciplinary heart failure management and end of life care.The St Vincent's potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care.Life expectancy for community-based patients with heart failure from time of diagnosis.Dilated cardiomyopathy and progressive familial intrahepatic cholestasis.Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure.Role of Monitoring Devices in Preventing Heart Failure Admissions.European Society of Cardiology Heart Failure Association Standards for delivering heart failure care.Heart Failure Virtual Consultation: bridging the gap of heart failure care in the community - A mixed-methods evaluation.The practice gap in heart failure-the elephant in the room.Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.Evolving Use of Natriuretic Peptides as Part of Strategies for Heart Failure Prevention.Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study.The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis.Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure?'The importance of planning for the future': Burden and unmet needs of caregivers' in advanced heart failure: A mixed methods study.Sleep-disordered breathing in chronic heart failure is highly variable when measured remotely using a novel non-contact biomotion sensor.B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension.Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction.Diabetes and complications of the heart in Sub-Saharan Africa: An urgent need for improved awareness, diagnostics and management.A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program.Usefulness of surveillance endomyocardial biopsy after pediatric cardiac transplantation.Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure.Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.Quantification of mitral regurgitation on cardiac computed tomography: comparison with qualitative and quantitative echocardiographic parameters.Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype.
P50
Q27015261-92923815-F2DB-477E-ABE7-B809B42935E4Q30362840-C8600B11-8B7F-4D9C-B4DF-B0EF3B3D3503Q30470370-EB7B9B7C-4263-4EA8-9D18-8B07AE635814Q34050866-9DEA5C1F-CEE6-4B5C-9BCC-F85A948B07EAQ34477882-CA0F5D41-B22E-404A-A5FB-7A61532A84A6Q35565357-B6B7759E-A6B4-4BEC-A48E-3648D88B6C57Q37261247-F1C5E26D-43C3-4A66-A81F-6B8F8E6950B2Q37906050-6CA786F0-54CC-4FFD-B3F5-80515A9A4C47Q37950808-C288E29A-021A-49F9-AF12-17B8FC543503Q38237578-932F2449-F877-41F5-A182-3FF7A3F64409Q38281239-4E84ACC0-413F-4B09-B5FE-F42A9CEE24F0Q38412235-92F3E89D-4C54-4543-B21B-80E4518C7B46Q38448978-7D5AFC1D-5016-4B04-8ABC-72DECC3EB2ADQ38486389-20B15EEE-B1EC-48BB-8C77-31B4EF652CE5Q38495175-8A4DA62E-FD43-4AE0-88CE-47AD06463F44Q38517990-B77AAF14-D9ED-40A9-9603-D9DB19AD777CQ38569425-5FBCF8B1-3192-4FBE-BBB9-EDDBC67B0FB6Q38643988-0FFDEA85-BA3D-4B7E-85AF-A51C8150E3E1Q38693716-2328016A-EF52-4014-8CBD-1AE9A7AF43B4Q38858284-D66CFE27-028C-4360-B0B1-45EE750C4491Q39016026-32BA9102-F1BC-4675-A5B1-6E74D8F68374Q39159036-AA1CE446-9C5B-4F62-BB81-0816BB71D1D0Q40809782-A9606C96-225D-4AA5-A8FC-F9012E201AB5Q43802128-C3AF36E5-AAED-4A00-88A5-1CA1351701D3Q45043245-CC1BDE48-C3A5-48B6-B701-BD7BDC944EE0Q46156825-3F85D990-DC92-4BE9-B2F7-6952F5EC0B40Q47269095-0108A08F-1D49-43C0-B8AE-96E0207D9E17Q47319154-697AF9CA-9635-44D3-A732-D4C027E565A0Q47752652-0D268103-CECF-4D8B-A2FB-628CE93F2875Q47785292-1C814B5E-8CF5-4EEE-94AA-42AD53E473D2Q48096616-9517CA56-28A9-41BC-8FC1-5939E48B4D3DQ48615907-CA6BF19D-2EBD-49FC-843D-E9828C551874Q49487884-D5776D7C-B8DF-4257-A73B-9A433C8FDBE3Q51329353-8C0B649F-C4F1-495E-B8CA-1C9988D42297Q51513632-E20E730B-F2C1-44CD-A52A-B4BCFFEB0E77Q52141958-09CF39D4-DF19-4A9E-9646-3A8960DC8A77Q53185348-DBE2465A-BE03-4B0B-832E-29ABD4312CBFQ53202012-DD04616D-D065-4C74-BAB7-2A1D5D448672Q53642395-F7ABEEEE-6FE0-443F-9B94-A88A56040180Q54495572-5C7F142D-486C-4D19-A954-7421D8F37753
P50
description
Irish cardiologist
@en
cardioloog uit Ierland
@nl
հետազոտող
@hy
name
Kenneth M McDonald
@ast
Kenneth M McDonald
@es
Kenneth M McDonald
@nl
Kenneth M McDonald
@sl
Kenneth M. McDonald
@en
type
label
Kenneth M McDonald
@ast
Kenneth M McDonald
@es
Kenneth M McDonald
@nl
Kenneth M McDonald
@sl
Kenneth M. McDonald
@en
altLabel
Ken McDonald
@en
Kenneth McDonald
@en
Kenneth Michael McDonald
@en
prefLabel
Kenneth M McDonald
@ast
Kenneth M McDonald
@es
Kenneth M McDonald
@nl
Kenneth M McDonald
@sl
Kenneth M. McDonald
@en
P106
P21
P27
P31
P4012
P496
0000-0001-8011-3301